Elzasonan

Elzasonan
Systematic (IUPAC) name
	4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one
Clinical data
Legal status	Uncontrolled;
Routes of; administration	Oral
Identifiers
CAS Number	220322-05-4
ATC code	none
PubChem	CID: 19544192
ChemSpider	5290108
UNII	933PJL964R
Chemical data
Formula	C22H23Cl2N3OS
Molecular mass	448.4085 g/mol
	SMILES Clc4c(Cl)cc(N1C(=O)C(\SCC1)=C\c3ccccc3N2CCN(C)CC2)cc4 ;
	InChI InChI=1S/C22H23Cl2N3OS/c1-25-8-10-26(11-9-25)20-5-3-2-4-16(20)14-21-22(28)27(12-13-29-21)17-6-7-18(23)19(24)15-17/h2-7,14-15H,8-13H2,1H3/b21-14- ; Key:LHYMPSWMHXUWSK-STZFKDTASA-N ;
(verify)

Elzasonan (CP-448,187) is a selective 5-HT_1B and 5-HT_1D receptor antagonist that was under development by Pfizer for the treatment of depression but was discontinued, possibly due to poor efficacy.^[1]^[2]^[3]^[4]^[5] By preferentially blocking 5-HT_1B and 5-HT_1D autoreceptors, elzasonan is thought to enhance serotonergic innervations originating from the raphe nucleus, thereby improving signaling to limbic regions like the hippocampus and prefrontal cortex and ultimately resulting in antidepressant effects.^[3]

References